Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) is now available.
Raily Aesthetic Medicine International Holdings has reallocated approximately HK$8.4 million of unutilised IPO net proceeds, originally earmarked for organic expansion of its aesthetic medical institutions network, to general working capital, with full deployment now targeted by 31 December 2026. The board determined that using the funds for establishing a new aesthetic medical hospital in Shanghai is no longer optimal, citing prolonged weakness in the city’s aesthetic medicine market following COVID-19 and the failure to identify a suitable institution there, and concluded that strengthening liquidity is currently more prudent for the company’s operations and financial stability.
The most recent analyst rating on (HK:2135) stock is a Hold with a HK$0.14 price target. To see the full list of analyst forecasts on Raily Aesthetic Medicine International Holdings Limited stock, see the HK:2135 Stock Forecast page.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited is a Hong Kong-listed provider of aesthetic medical services, operating a network of aesthetic medical institutions in China. The group focuses on treatments delivered through specialized clinics and hospitals, supported by investments in medical equipment, consumables and brand promotion to grow its presence in the Chinese aesthetic medicine market.
Average Trading Volume: 892,044
Technical Sentiment Signal: Buy
Current Market Cap: HK$83.56M
For an in-depth examination of 2135 stock, go to TipRanks’ Overview page.